Farmacos en Ensayos Clinicos basados en RNAi . Uno de ellos nuestro Farmaco para Glaucoma SYL040012 .

Sylentis

SYL040012 is an siRNA designed to inhibit adrenergic receptor beta-2. Sylentis’ first RNAi drug candidate, the glaucoma therapy began a phase I trial in September.

...